• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

采用高效液相色谱法测定血浆和尿液中新型磷酸二酯酶V抑制剂DA-8159的含量。

Determination of a new phosphodiesterase V inhibitor, DA-8159, in plasma and urine by high-performance liquid chromatography.

作者信息

Shim Hyun Joo, Lee Eun Joo, Jung Young Hee, Kim So Hee, Kim Soon Hoe, Yoo Moohi, Kwon Jong Won, Kim Won Bae, Lee Myung Gull

机构信息

College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University, San 56-1, Shinlim-Dong, Kwanak-Gu, Seoul 151-742, South Korea.

出版信息

J Pharm Biomed Anal. 2002 Oct 15;30(3):527-33. doi: 10.1016/s0731-7085(02)00397-7.

DOI:10.1016/s0731-7085(02)00397-7
PMID:12367677
Abstract

A high-performance liquid chromatographic (HPLC) method using liquid-liquid extraction for sample preparation was developed for the determination of a new phosphodiesterase V inhibitor, DA-8159, in rat plasma and urine using sildenafil citrate as an internal standard. A 100 microl aliquot of 0.1 M Na(2)CO(3) (containing sildenafil citrate, 3 microg/ml as free sildenafil) and a 1 ml aliquot of ether were added to a 100 microl aliquot of biological samples (urine samples were diluted 20 times with distilled water). After vortex centrifugation at 9000 x g for 3 min, the ether layer was collected and dried under nitrogen gas. The residue was reconstituted with a 150 microl aliquot of the mobile phase, centrifuged, and a 100 microl aliquot of the supernatant was injected onto a reversed-phase column. The mobile phases, 20 mM KH(2)PO(4) (pH 4.7):acetonitrile (70:30, v/v for plasma and tissue samples, and 75:25, v/v for urine samples), were run at a flow rate of 1.0 ml/min. The column effluent was monitored by an ultraviolet detector set at 292 nm. The retention times for DA-8159 and the internal standard were approximately 10.7 and 9.1 min, respectively, in plasma and tissue samples and the corresponding values in urine samples were 47 and 33 min. The detection limits for DA-8159 in rat plasma and urine were 20 and 100 ng/ml, respectively. The coefficients of variation of the assay were generally low: below 10% for plasma and 9.9% for urine. No interferences from endogenous substances were found.

摘要

建立了一种高效液相色谱(HPLC)法,采用液-液萃取进行样品制备,以枸橼酸西地那非为内标,用于测定大鼠血浆和尿液中一种新型磷酸二酯酶V抑制剂DA-8159。将100 μl 0.1 M Na₂CO₃(含枸橼酸西地那非,以游离西地那非计为3 μg/ml)和1 ml乙醚加入100 μl生物样品(尿液样品用蒸馏水稀释20倍)中。在9000×g下涡旋离心3分钟后,收集乙醚层并在氮气下干燥。残渣用150 μl流动相复溶,离心,取100 μl上清液注入反相柱。流动相为20 mM KH₂PO₄(pH 4.7):乙腈(血浆和组织样品为体积比70:30,尿液样品为体积比75:25),流速为1.0 ml/min。柱流出物用设定在292 nm的紫外检测器监测。在血浆和组织样品中,DA-8159和内标的保留时间分别约为10.7分钟和9.1分钟,在尿液样品中的相应值分别为47分钟和33分钟。大鼠血浆和尿液中DA-8159的检测限分别为20 ng/ml和100 ng/ml。该测定法的变异系数一般较低:血浆中低于10%,尿液中为9.9%。未发现内源性物质的干扰。

相似文献

1
Determination of a new phosphodiesterase V inhibitor, DA-8159, in plasma and urine by high-performance liquid chromatography.采用高效液相色谱法测定血浆和尿液中新型磷酸二酯酶V抑制剂DA-8159的含量。
J Pharm Biomed Anal. 2002 Oct 15;30(3):527-33. doi: 10.1016/s0731-7085(02)00397-7.
2
Sensitive liquid chromatography assay with ultraviolet detection for a new phosphodiesterase V inhibitor, DA-8159, in human plasma and urine.用于检测人血浆和尿液中新型磷酸二酯酶V抑制剂DA - 8159的带紫外检测的灵敏液相色谱分析法。
J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Oct 5;795(2):179-86. doi: 10.1016/s1570-0232(03)00565-8.
3
Determination of a new reversible proton pump inhibitor, DBM-819, in human plasma and urine, and rat tissue homogenates by high-performance liquid chromatography.
J Pharm Biomed Anal. 2002 Oct 15;30(3):511-8. doi: 10.1016/s0731-7085(02)00399-0.
4
Determination of 1-(3-fluoro-4-hydroxy-5-mercaptomethyltetrahydrofuran-2-yl)-5-methyl-1H-pyrimidine-2,4-dione in rat plasma and urine by high-performance liquid chromatography.高效液相色谱法测定大鼠血浆和尿液中1-(3-氟-4-羟基-5-巯基甲基四氢呋喃-2-基)-5-甲基-1H-嘧啶-2,4-二酮的含量
J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Apr 25;803(2):367-70. doi: 10.1016/j.jchromb.2004.01.007.
5
High-performance liquid chromatographic analysis of DA-7867, a new oxazolidinone, in human plasma and urine and in rat tissue homogenates.新型恶唑烷酮类药物DA-7867在人血浆、尿液及大鼠组织匀浆中的高效液相色谱分析
J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Sep 5;794(2):397-403. doi: 10.1016/s1570-0232(03)00476-8.
6
Determination of a new carbapenem antibiotic, DA-1131, in rat plasma, urine, and bile by column-switching high-performance liquid chromatography.采用柱切换高效液相色谱法测定大鼠血浆、尿液和胆汁中新型碳青霉烯类抗生素DA-1131的含量。
Res Commun Mol Pathol Pharmacol. 1996 Nov;94(2):171-80.
7
High-performance liquid chromatographic analysis of nitrendipine in human plasma using ultraviolet detection and single-step solid-phase sample preparation.采用紫外检测和单步固相样品制备法对人血浆中尼群地平进行高效液相色谱分析。
J Pharm Biomed Anal. 2003 Jun 1;32(2):387-92. doi: 10.1016/s0731-7085(03)00129-8.
8
Determination of a new isoquinolinedione derivative, 7-anilino-5,8-isoquinolinedione, in plasma, urine and tissue homogenates by high-performance liquid chromatography.采用高效液相色谱法测定血浆、尿液和组织匀浆中的新型异喹啉二酮衍生物7-苯胺基-5,8-异喹啉二酮。
J Pharm Biomed Anal. 2002 Oct 15;30(3):519-26. doi: 10.1016/s0731-7085(02)00398-9.
9
Determination of a chemopreventive agent, Oltipraz, in rat plasma and urine by high-performance liquid chromatography.采用高效液相色谱法测定大鼠血浆和尿液中的化学预防剂奥替普拉。
Res Commun Mol Pathol Pharmacol. 2001 Jul-Aug;110(1-2):133-8.
10
Determination of a chemoprotective agent, 2-(allylthio)pyrazine, in plasma, urine and tissue homogenates by high-performance liquid chromatography.采用高效液相色谱法测定血浆、尿液和组织匀浆中的化学保护剂2-(烯丙硫基)吡嗪。
J Chromatogr B Biomed Sci Appl. 1998 Jun 12;710(1-2):239-42. doi: 10.1016/s0378-4347(98)00097-8.

引用本文的文献

1
Fabrication, appraisal, and transdermal permeation of sildenafil citrate-loaded nanostructured lipid carriers versus solid lipid nanoparticles.载有枸橼酸西地那非的纳米结构脂质载体与固体脂质纳米粒的制备、评价及经皮渗透。
Int J Nanomedicine. 2011;6:3195-205. doi: 10.2147/IJN.S25825. Epub 2011 Dec 6.
2
Effect of ketoconazole on the pharmacokinetics of udenafil in healthy Korean subjects.酮康唑对健康韩国受试者中乌地那非药代动力学的影响。
Br J Clin Pharmacol. 2010 Mar;69(3):307-10. doi: 10.1111/j.1365-2125.2009.03601.x.
3
Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects.
新型磷酸二酯酶-5抑制剂 udenafil 在健康韩国年轻受试者中的安全性、耐受性和药代动力学
Br J Clin Pharmacol. 2008 Jun;65(6):848-54. doi: 10.1111/j.1365-2125.2008.03107.x. Epub 2008 Mar 3.
4
Pharmacokinetic interaction between DA-8159, a new erectogenic, and metformin in rats: competitive inhibition of metabolism via hepatic CYP3A1/2.新型勃起功能改善药物DA-8159与二甲双胍在大鼠体内的药代动力学相互作用:通过肝脏CYP3A1/2对代谢的竞争性抑制
Br J Pharmacol. 2008 Apr;153(7):1568-78. doi: 10.1038/sj.bjp.0707680. Epub 2008 Jan 21.
5
Pharmacokinetic and pharmacodynamic consequences of inhibition of terazosin metabolism via CYP3A1 and/or 3A2 by DA-8159, an erectogenic, in rats.大鼠中,壮阳药DA - 8159通过CYP3A1和/或3A2抑制特拉唑嗪代谢的药代动力学和药效学后果。
Br J Pharmacol. 2007 May;151(1):24-34. doi: 10.1038/sj.bjp.0707192. Epub 2007 Mar 12.